Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

NCT02963090 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lack of enrollment

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Topotecan
DRUG: Pembrolizumab

Sponsor

Alliance Foundation Trials, LLC.

Collaborators

[object Object]